Inflammation plays a role in the development and progression of type 2 diabetes macroangiopathy. Interleukin 33 (IL-33) drives production of Th2-associated cytokines. The soluble form of suppression of tumorigenicity 2 (sST2) acting as a decoy receptor blocks IL-33 and tones down Th2 inflammatory response. We investigated the role of sST2 as a predictor of CV and all-cause mortality in a cohort of patients affected by established atherosclerotic disease.
Cardellini, M., Rizza, S., Casagrande, V., Cardolini, I., Ballanti, M., Davato, F., et al. (2019). Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. ACTA DIABETOLOGICA, 56(3), 273-280 [10.1007/s00592-018-1230-z].
Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects
Cardellini M.;Rizza S.;Casagrande V.;Ballanti M.;Davato F.;Porzio O.;Canale M. P.;Legramante J. M.;Mavilio M.;Menghini R.;Martelli E.;Farcomeni A.;Federici M.
2019-01-01
Abstract
Inflammation plays a role in the development and progression of type 2 diabetes macroangiopathy. Interleukin 33 (IL-33) drives production of Th2-associated cytokines. The soluble form of suppression of tumorigenicity 2 (sST2) acting as a decoy receptor blocks IL-33 and tones down Th2 inflammatory response. We investigated the role of sST2 as a predictor of CV and all-cause mortality in a cohort of patients affected by established atherosclerotic disease.| File | Dimensione | Formato | |
|---|---|---|---|
|
Cardellini2019_Article_SolubleST2IsABiomarkerForCardi.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
1.23 MB
Formato
Adobe PDF
|
1.23 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
